Real-World Use of Sipuleucel-T in Metastatic Prostate Cancer
Posted: Wednesday, April 8, 2020
Adding the immunotherapy sipuleucel-T to oral therapy for metastatic castration-resistant prostate cancer significantly reduced the risk of death, no matter what point it was given, according to results of a retrospective analysis of data on almost 7,000 men presented at the 2020 Genitourinary Cancers Symposium in San Francisco (Abstract 42). Rana R. McKay, MD, of Moores Cancer Center at the University of California, San Diego, and colleagues found that patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide as well as sipuleucel-T, 3-year survival was significantly higher than in those who did not receive sipuleucel-T (48% vs. 28%; P < .0001).
The reduction in risk of death was calculated to be 45%. In those who were treated with sipuleucel-T, the median overall survival was significantly higher than in those who did not receive the immunotherapy (35.2 vs. 20.7 months; P < .0001). “This magnitude of risk reduction is a compelling finding,” stressed Dr. McKay in a press release.
In the cohort of 6,853 Medicare fee-for-service beneficiaries, more than 150 variations of treatment sequences were discovered. Thus, discerning which sequences might produce the best survival results is the goal of ongoing statistical analysis. “We’re [also] looking at other variables that could impact outcomes,” Dr. McKay said.
Disclosure: For full disclosures of the study authors, visit coi.asco.org.
